Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.85 |
| ▸ | MAOA | P21397 | 5/20 | 0.85 |
| ▸ | BCHE | P06276 | 1/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.84 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.75 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.75 |
| ▸ | CTSL | P07711 | 1/20 | 0.72 |
| ▸ | CTSB | P07858 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.66 |
| ▸ | KRAS | P01116 | 2/20 | 0.63 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733854 | 1.00 | MAOB (0.85) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL8977012 | 0.94 | MAOB (0.76) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL8965792 | 0.94 | MAOB (0.76) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL9136940 | 0.94 | MAOB (0.80) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL8965786 | 0.94 | MAOB (0.76) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL9136943 | 0.94 | MAOB (0.80) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL8977005 | 0.94 | MAOB (0.76) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL3041716 | 0.92 | MAOB (0.74) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL9137109 | 0.92 | MAOB (0.74) | MAOBMAOABCHECYP1B1HSPD1 | |
| SCHEMBL3052864 | 0.92 | MAOB (0.74) | MAOBMAOABCHECYP1B1HSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119318957-A | For synthesizing photosensitivity catalyst for diamine compound | 青岛伯川特聚科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20040110757-A1 | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | ARRHENIUS THOMAS (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1370250-A2 | FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | disclosed |
| WO-2002076438-A2 | FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-10-03 | — | — | WO | disclosed |
| EP-0996432-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUMINSTITUT (DK) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999000114-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUM INSTITUT (DK) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | MAOB 943/4885MAOA 904/4885BCHE 3521/4885 |
| US-20040110757-A1 | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | FLT1, FLT4, TEK | MAOB 744/4885MAOA 1200/4885BCHE 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.